Dr. Camozzi earned his MD and PhD from the School of Medicine, National University of Buenos Aires (Argentina), and holds degrees in Paediatrics, Neonatology, Clinical Pharmacology and Neuropsychiatry.
About Amsterdam Molecular Therapeutics
AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry. AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.
Certain statements in this press release are
"forward-looking statements" including
those that refer to management's plans and expectations for future
operations, prospects and financial condition. Words such as
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2010 PR Newswire.
All rights reserved